



HAL
open science

Coxiella burnetii Lipopolysaccharide: What Do We Know?

Prasad Abnave, Xavier Muracciole, Eric Ghigo

► **To cite this version:**

Prasad Abnave, Xavier Muracciole, Eric Ghigo. Coxiella burnetii Lipopolysaccharide: What Do We Know?. International Journal of Molecular Sciences, 2017, 18 (12), pp.E2509. 10.3390/ijms18122509 . hal-01729778

HAL Id: hal-01729778

<https://hal.science/hal-01729778v1>

Submitted on 23 Apr 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Review

Coxiella burnetii Lipopolysaccharide: What Do We Know?

Prasad Abnave ¹, Xavier Muracciole ² and Eric Ghigo ^{3,*}

¹ Department of Zoology, University of Oxford, Tinbergen Building, South Parks Road, Oxford OX1 3PS, UK; prasadabnave@gmail.com

² Department of Radiotherapy Oncology, CHU de la Timone, Assistance Publique-Hopitaux Marseille, 13385 Marseille, France; xavier.muracciole@gmail.com

³ Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut Hospitalier Universitaire Méditerranée-Infection, 19-21 Bd Jean Moulin, CEDEX 05, 13385 Marseille, France

* Correspondence: eric.ghigo@gmail.com; Tel.: +33-(0)4-137-32405

Received: 29 September 2017; Accepted: 21 November 2017; Published: 23 November 2017

Abstract: A small gram-negative bacterium, *Coxiella burnetii* (*C. burnetii*), is responsible for a zoonosis called Q fever. *C. burnetii* is an intracellular bacterium that can survive inside microbicidal cells like monocytes and macrophages by hijacking several functions of the immune system. Among several virulence factors, the lipopolysaccharide (LPS) of *C. burnetii* is one of the major factors involved in this immune hijacking because of its atypical composition and structure. Thus, the aim of this mini-review is to summarize the repressive effects of *C. burnetii* LPS on the antibacterial immunity of cells.

Keywords: lipopolysaccharide; *Coxiella burnetii*; Q fever; phagosome; virenose

1. Introduction

Coxiella burnetii is an intracellular bacterium responsible for a worldwide zoonosis known as Q fever [1,2]. After primary infection, approximately 60% of humans remain asymptomatic, while 40% manifest clinical signs consisting of isolated fever, hepatitis, and pneumonia [3]. The principal clinical manifestation of Q fever is endocarditis with a lethal prognosis without treatment. The treatment involves a combination of doxycycline and hydroxychloroquine [1,3]. However, this long-term treatment carries the persistent risk of relapse [4].

C. burnetii is a small bacterium measuring approximately 0.2 to 0.4 µm wide and 0.4 to 1 µm long, and it has been classified in the *Proteobacteria* subdivision based on its 16S ribosomal RNA sequence. As *C. burnetii* harbours lipopolysaccharide (LPS) in its membrane, it is defined as a gram-negative bacterium. Though *C. burnetii* is not stained by Gram stain, it can be stained by Gimenez stain [5]. *C. burnetii* primarily infects domestic ruminants and pets, but arthropods have also been found to be infected. In animals, the infection is asymptomatic but induces abortions in livestock. Both abortion and parturition contribute to the bacteria spreading into the environment, since the placenta of infected animals contains large amounts of *C. burnetii*. Contamination via aerosols also remains the major route of infection in both animals and humans [3,6]. *C. burnetii* has been categorized as a biological weapon due to its high infectivity, the possibility of producing large quantities of bacteria, its environmental stability through a sporulation-like mechanism, and its dispersion via aerosolization [7,8]. *C. burnetii* was likely used as a bio-weapon during World War II, as a Q fever outbreak was observed during this time among army troops [9].

C. burnetii resides primarily within myeloid cells (monocytes and macrophages) [10,11] but has also been shown to infect trophoblasts [12] and adipocytes [13]. The adaptation of *C. burnetii* to its environment is probably critical for its survival. To survive within its host, *C. burnetii* interferes

with the host's antimicrobial response (immunity and phagolysosome biogenesis). For this purpose, *C. burnetii* has an arsenal of virulence factors [14–17], including LPS [18]. The molecular variations observed in *C. burnetii* LPS, a major component of its outer membrane, contribute to its pathogenic properties [19–21]. Moreover, the intracellular fate of virulent *C. burnetii* in myeloid cells is also determined by its LPS composition [18].

2. *Coxiella burnetii* LPS: Structure and Composition

As observed in enterobacteria, *C. burnetii* displays antigenic variations, from a smooth-rough form called Phase I to a rough form known as Phase II. The Phase I form is isolated from natural sources and defined as a virulent form of *C. burnetii*. It is characterized by full-length LPS and survives inside monocytes and macrophages [10,11]. After several passages of the virulent *C. burnetii* in embryonated eggs or tissue culture, an irreversible modification is observed in the molecular weight of *C. burnetii* LPS. *C. burnetii* harbouring a truncated LPS is defined as an avirulent microorganism and eliminated by monocytes and macrophages [22,23]. This avirulent form does not exist in the natural environment. It was shown that this LPS modification occurs due to a genomic deletion [3]. The difference between the virulent and avirulent forms of *C. burnetii* lies in the *O*-antigen; specifically, LPS from virulent *C. burnetii* has an *O*-antigen that contains unusual sugars, L-virenose, dihydrohydroxystreptose, and galactosamine uronyl- α -(1,6)-glucosamine residues, whereas LPS from the avirulent form does not have any *O*-antigen [19–21,24–32]. Virenose and dihydrohydroxystreptose have not been found in any other enterobacterial LPSs and are thus unique biomarkers of virulent *C. burnetii*. Interestingly, the lipid A molecules of both virulent and avirulent *C. burnetii* display the same ionic species and fragmentation profiles in mass spectrometry, suggesting that they have very similar and likely identical structures. The *C. burnetii* lipid A structure differs considerably from the published standard form of enterobacterial lipid A. An analysis of lipid A from *C. burnetii* identified two major tetra-acylated molecular species sharing the classical backbone of a dephosphorylated GlcN (acylated D-glucosamine residues) disaccharide in which both GlcN I and GlcN II carry an amide-linked iso or normal (n) C16:0(3-OH) [24,33]. The core polysaccharide is conserved between virulent and avirulent *C. burnetii* LPSs and contains a heptasaccharide localized in the proximal region of lipid A. The heptasaccharide is formed by two terminal D-mannoses (Man), 2- and 3,4-linked D-glycero-D-manno-heptoses, and terminal 4- and 4,5-linked 3-deoxy-D-manno-oct-2-ulosonic acid residues [20,29]. It is important to note that a third *C. burnetii* LPS has been identified as an intermediate-length LPS at the surface of the Nine Mile Crazy strain [34]. Large chromosomal deletions have been found in these avirulent *C. burnetii* Nine Mile and Nine Mile Crazy strains [35]. These deletions eliminate open reading frames involved in the biosynthesis of *O*-antigen sugars, including the rare sugar virenose [35]. The description of the virenose biosynthesis pathway suggests the formation of GDP- β -D-virenose via the modification of GDP-L-fucose by the addition of a methyl group at position C3'', and perhaps the open reading frame CBU0691, and the inversion of the stereochemistry at position C2'' [36].

3. *C. burnetii* LPS Interferes with Phagocytosis

It is known that phagocytosis efficiency depends on the activation of phagocytic receptor CR3 (complement receptor-3) through α v β 3 integrin and CD47 (integrin-associated protein). *C. burnetii*, via its LPS, subverts receptor-mediated phagocytosis [22] by inhibiting the interplay between integrins, including CR3, remodelling the actin cytoskeleton organization, and activating protein tyrosine kinases. This strategy possibly determines the evolution of Q fever. *C. burnetii*, via its LPS, interacts with macrophages through α v β 3 integrins, and avoids internalization by inhibiting the interaction between α v β 3 integrins and CR3, which is essential for bacterial uptake [22,37]. Inhibition of the interplay between α v β 3 integrins and CR3 leads to poor internalization of virulent *C. burnetii* compared with its avirulent form, which harbours a truncated LPS and is largely internalized by monocytes and macrophages. Interestingly, the inhibitory mechanism mediated by virulent *C. burnetii* through its LPS does not target CD47 [22]. Note that CR3, not α v β 3 integrin, is excluded from the cytoskeleton

protrusions formed during the cytoskeleton reorganization induced by virulent *C. burnetii* LPS, thus decreasing the efficiency of phagocytosis [22,37,38]. An in-depth analysis has demonstrated that the uptake of avirulent *C. burnetii* requires both CD11b/CD18 and CR3, whereas virulent organism internalization does not involve CR3. It has been shown that the LPS from virulent *C. burnetii* prevents the activation of CR3 by interfering with its lectin sites [22]. This leads to conformational changes in the I domain and in the exposure of activation epitopes and cytoskeleton reorganization [39].

Finally, virulent *C. burnetii* induces early protein tyrosine kinase activation as well as the tyrosine phosphorylation of two Src-related kinases: Hck and Lyn [40]. By contrast, the avirulent form does not stimulate protein tyrosine kinases. Tyrosine-phosphorylated proteins co-localize with F-actin inside protrusions. Cell membrane protrusions are induced via the activation of protein tyrosine kinases by *C. burnetii* LPS, which in turn down-modulates *C. burnetii* uptake [40,41]. The use of protein tyrosine kinase inhibitors rescues *C. burnetii* phagocytosis. It has been hypothesized that the membrane ruffling induced by protein tyrosine kinase activation may interfere with the co-localization of CR3 with $\alpha\text{v}\beta\text{3}$ integrin and *C. burnetii* [42,43]. It has also been shown that *C. burnetii* LPS interferes with Toll Like Receptor (TLR)-2 and TLR-4 signalling through cytoskeleton reorganization [38,41,42]. Indeed, cytoskeleton reorganization induces a redistribution of TLR-2 and TLR-4 on the membrane of macrophages. This redistribution disrupts the colocalization between TLR-2 and TLR-4, in contrast to what is observed in macrophages challenged with LPS from the avirulent strain of *C. burnetii*. Co-immunoprecipitation experiments have revealed that a possible physical link between TLR-2 and TLR-4 is broken in cells challenged with virulent *C. burnetii* LPS. As a consequence, p38 α Mitogen-Activated Protein Kinase (MAPK) is not activated in macrophages challenged with virulent *C. burnetii* and LPS extracted from virulent *C. burnetii* [18,41,44]. However, the existence of a TLR2/TLR4/p38 α MAPK axis in *C. burnetii* infection remains to be demonstrated.

4. *C. burnetii* LPS Interferes with the Antibacterial Immune Response

Macrophage immune polarization is reoriented by *C. burnetii* to deactivate the macrophage microbicidal response [45,46]. Indeed, *C. burnetii* is responsible for atypical M2 macrophage activation, and it has been shown to induce expression of M2 polarization-related genes (transforming growth factor- β1 , interleukin (IL)-1 receptor antagonist, Chemokine (C-C motif) ligand (CCL)18, mannose receptor, arginase-1). By contrast, the expression of genes related to M1 polarization (tumor necrosis factor, CD80, C-C chemokine receptor type (CCR)7) is inhibited. It is interesting to note that the expression of arginase-1 is associated with the absence of nitric oxide production, while the expression of the *Interleukin (IL)-6* and *Chemokine (C-X-C motif) ligand (CXCL)8* genes (M1-related genes) is increased, although their proteins are weakly secreted [45]. In addition, monocytes produce high levels of IL-10 in response to *C. burnetii* or its LPS. IL-10 favours the persistence of *C. burnetii* by down-regulating the expression of tumor necrosis factor [47–49]. It is also responsible for the expression of *Programmed cell Death protein (PD)-1* by monocytes in vitro, and most likely, in patients with Q fever endocarditis. The LPS of *C. burnetii* does not induce the expression of PD-1 by monocytes. PD-1 delivers an inhibitory signal to T cells [50,51], and its expression in Q fever contributes to the immune suppression observed in Q fever endocarditis [52].

5. *C. burnetii* LPS as a Determinant Factor in Phagolysosome Biogenesis

In human macrophages, it has been observed that, in contrast to virulent *C. burnetii*, the avirulent form is quickly eliminated in degradative phagolysosome-like compartments [11,47]. Their replication is partially controlled in resident mouse peritoneal macrophages [53]. Immediately after phagocytosis, both virulent and avirulent forms of *C. burnetii* are localized within an early phagosome, transiently harbouring EEA1 (early endosome auto-antigen-1). This early phagosome undergoes a maturation process and is transformed into a late phagosome, presenting the markers Lamp-1, CD63, mannose-6-phosphate receptor, and V-H+ATPase and possessing an acidic pH. The major difference between the compartments containing virulent and avirulent forms of *C. burnetii* is the absence of the

small GTPase Rab7 at the surface of the phagosome containing the virulent *C. burnetii* [11,17,18,23]. In contrast to the vacuole with avirulent bacteria, the phagosome containing the virulent strain of *C. burnetii* does not mature in phagolysosomes [23]. Surprisingly, the intracellular trafficking of *C. burnetii* LPS is similar to the trafficking of intact bacteria. Indeed, the LPSs from virulent and avirulent *C. burnetii* traffic through early phagosomes characterized by the presence of the small GTPase Rab5 and EEA1 [18,54]. Nevertheless, endosomes containing LPS purified from avirulent bacteria develop into late endosomes (Rab7, Lamp1) and then into lysosomes containing the lysosomal enzyme cathepsin D. The endosomes transporting LPS isolated from virulent bacteria mature from early to late endosomes but do not become lysosomes. Interestingly, in terms of intact *C. burnetii*, late endosomes containing LPS do not express the Rab7 protein on their surface [18,23,55]. This result suggests that LPS is responsible for blocking phagolysosome maturation induced by *C. burnetii*. Investigations of *C. burnetii* LPS have demonstrated that the LPS from pathogenic *C. burnetii* does not induce the phosphorylation of p38 α MAPK by Mitogen-Activated Protein Kinase Kinase (MKK)6. This defect in the activation of p38 α MAPK prevents the serine phosphorylation (S796E) of Vps41. In the absence of phosphorylation, Vps41 does not promote the targeting of the HOPS (homotypic fusion and protein sorting) complex to endosome–vacuole fusion sites, and thus it fails to recruit the GTP-bound Rab7 required for phagosome–lysosome fusion [56–61]. The absence of p38 α MAPK activation is most likely due to the engagement of TLR4 by two unusual sugars, virenose and dihydrohydroxystreptose, present in the LPS of pathogenic *C. burnetii*. Thus, LPS from virulent *C. burnetii* acts as an antagonist of TLR-4.

6. Concluding Remarks

Collectively, this evidence highlights the importance of LPS and its composition in the strategies used by *C. burnetii* to infect cells and develop an efficient infection that leads to Q fever. It is interesting to observe that the particular composition of *C. burnetii* LPS allows several axes of the immune response to be modulated, ranging from phagocytosis to vesicular trafficking. Certainly, the virulence of *C. burnetii* does not only depend on LPS, as other virulence factors have been identified in *C. burnetii* [11,14]. The recent successful culturing of *C. burnetii* in axenic conditions might significantly develop our understanding of *C. burnetii* infection by facilitating the identification of new virulence factors [62,63]. Further work is required to understand the mechanisms implied in anti-microbicidal response hijacking. It might be interesting to generate transgenic *Escherichia coli* expressing the LPSs from both the virulent and avirulent *C. burnetii* to better understand LPS action. Similarly, as several new *C. burnetii* strains that cause severe Q fever have been isolated [2], it will be interesting to analyse their LPS composition to determine if the virulence and clinical issues observed are linked to any particular structure or composition of LPS.

Acknowledgments: This work was supported by IHU Méditerranée Infection.

Author Contributions: Prasad Abnave, Xavier Muracciole and Eric Ghigo wrote the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Maurin, M.; Benoliel, A.M.; Bongrand, P.; Raoult, D. Phagolysosomal alkalization and the bactericidal effect of antibiotics: The *Coxiella burnetii* paradigm. *J. Infect. Dis.* **1992**, *166*, 1097–1102. [[CrossRef](#)] [[PubMed](#)]
2. Eldin, C.; Melenotte, C.; Mediannikov, O.; Ghigo, E.; Million, M.; Edouard, S.; Mege, J.L.; Maurin, M.; Raoult, D. From Q fever to *Coxiella burnetii* infection: A paradigm change. *Clin. Microbiol. Rev.* **2017**, *30*, 115–190. [[CrossRef](#)] [[PubMed](#)]
3. Maurin, M.; Raoult, D. Q fever. *Clin. Microbiol. Rev.* **1999**, *12*, 518–553. [[PubMed](#)]
4. Houpikian, P.; Habib, G.; Mesana, T.; Raoult, D. Changing clinical presentation of Q fever endocarditis. *Clin. Infect. Dis.* **2002**, *34*, E28–E31. [[CrossRef](#)] [[PubMed](#)]
5. Gimenez, D.F. Staining rickettsiae in yolk-sac cultures. *Stain Technol.* **1964**, *39*, 135–140. [[CrossRef](#)] [[PubMed](#)]

6. Melenotte, C.; Lepidi, H.; Nappes, C.; Bechah, Y.; Audoly, G.; Terras, J.; Raoult, D.; Bregeon, F. Mouse model of *Coxiella burnetii* aerosolization. *Infect. Immun.* **2016**, *84*, 2116–2123. [[CrossRef](#)] [[PubMed](#)]
7. McCaul, T.F.; Williams, J.C. Developmental cycle of *Coxiella burnetii*: Structure and morphogenesis of vegetative and sporogenic differentiations. *J. Bacteriol.* **1981**, *147*, 1063–1076. [[PubMed](#)]
8. Oswald, W.; Thiele, D. A sporulation gene in *Coxiella burnetii*? *Zent. Vet. Reihe B J. Vet. Med.* **1993**, *40*, 366–370. [[CrossRef](#)]
9. Madariaga, M.G.; Rezai, K.; Trenholme, G.M.; Weinstein, R.A. Q fever: A biological weapon in your backyard. *Lancet* **2003**, *3*, 709–721. [[CrossRef](#)]
10. Baca, O.G.; Li, Y.P.; Kumar, H. Survival of the Q fever agent *Coxiella burnetii* in the phagolysosome. *Trends Microbiol.* **1994**, *2*, 476–480. [[CrossRef](#)]
11. Ghigo, E.; Colombo, M.I.; Heinzen, R.A. The *Coxiella burnetii* parasitophorous vacuole. *Adv. Exp. Med. Biol.* **2012**, *984*, 141–169. [[PubMed](#)]
12. Ben Amara, A.; Ghigo, E.; Le Priol, Y.; Lepolard, C.; Salcedo, S.P.; Lemichez, E.; Bretelle, F.; Capo, C.; Mege, J.L. *Coxiella burnetii*, the agent of Q fever, replicates within trophoblasts and induces a unique transcriptional response. *PLoS ONE* **2010**, *5*, e15315. [[CrossRef](#)] [[PubMed](#)]
13. Bechah, Y.; Verneau, J.; Ben Amara, A.; Barry, A.O.; Lepolard, C.; Achard, V.; Panicot-Dubois, L.; Textoris, J.; Capo, C.; Ghigo, E.; et al. Persistence of *Coxiella burnetii*, the agent of Q fever, in murine adipose tissue. *PLoS ONE* **2014**, *9*, e97503. [[CrossRef](#)] [[PubMed](#)]
14. Qiu, J.; Luo, Z.Q. Legionella and coxiella effectors: Strength in diversity and activity. *Nat. Rev.* **2017**, *15*, 591–605. [[CrossRef](#)] [[PubMed](#)]
15. Weber, M.M.; Chen, C.; Rowin, K.; Mertens, K.; Galvan, G.; Zhi, H.; Dealing, C.M.; Roman, V.A.; Banga, S.; Tan, Y.; et al. Identification of *Coxiella burnetii* type IV secretion substrates required for intracellular replication and coxiella-containing vacuole formation. *J. Bacteriol.* **2013**, *195*, 3914–3924. [[CrossRef](#)] [[PubMed](#)]
16. Newton, H.J.; Roy, C.R. The *Coxiella burnetii* dot/icm system creates a comfortable home through lysosomal renovation. *mBio* **2011**, *2*. [[CrossRef](#)] [[PubMed](#)]
17. Ghigo, E.; Pretat, L.; Desnues, B.; Capo, C.; Raoult, D.; Mege, J.L. Intracellular life of *Coxiella burnetii* in macrophages. *Ann. N. Y. Acad. Sci.* **2009**, *1166*, 55–66. [[CrossRef](#)] [[PubMed](#)]
18. Barry, A.O.; Boucherit, N.; Mottola, G.; Vadovic, P.; Trouplin, V.; Soubeyran, P.; Capo, C.; Bonatti, S.; Nebreda, A.; Toman, R.; et al. Impaired stimulation of p38 α -MAPK/VPS41-hops by LPS from pathogenic *Coxiella burnetii* prevents trafficking to microbicidal phagolysosomes. *Cell Host Microbe* **2012**, *12*, 751–763. [[CrossRef](#)] [[PubMed](#)]
19. Lukacova, M.; Barak, I.; Kazar, J. Role of structural variations of polysaccharide antigens in the pathogenicity of gram-negative bacteria. *Clin. Microbiol. Infect.* **2008**, *14*, 200–206. [[CrossRef](#)] [[PubMed](#)]
20. Toman, R.; Skultety, L.; Ihnatko, R. *Coxiella burnetii* glycomics and proteomics—Tools for linking structure to function. *Ann. N. Y. Acad. Sci.* **2009**, *1166*, 67–78. [[CrossRef](#)] [[PubMed](#)]
21. Stulik, J.; Toman, R.; Butaye, P.; Ulrich, R.G. Lipopolysaccharides of *Coxiella burnetii*: Chemical composition and structure, and their role in diagnosis of Q fever. In *BSL3 and BSL4 Agents: Proteomics, Glycomics, and Antigenicity*; Hoboken, N., Ed.; Wiley-Blackwell: Hoboken, NJ, USA, 2011; Volume 1166, pp. 115–123.
22. Capo, C.; Lindberg, F.P.; Meconi, S.; Zaffran, Y.; Tardei, G.; Brown, E.J.; Raoult, D.; Mege, J.L. Subversion of monocyte functions by *Coxiella burnetii*: Impairment of the cross-talk between $\alpha\text{v}\beta\text{3}$ integrin and CR3. *J. Immunol.* **1999**, *163*, 6078–6085. [[PubMed](#)]
23. Ghigo, E.; Capo, C.; Tung, C.H.; Raoult, D.; Gorvel, J.P.; Mege, J.L. *Coxiella burnetii* survival in THP-1 monocytes involves the impairment of phagosome maturation: IFN- γ mediates its restoration and bacterial killing. *J. Immunol.* **2002**, *169*, 4488–4495. [[CrossRef](#)] [[PubMed](#)]
24. Alexander, C.; Rietschel, E.T. Bacterial lipopolysaccharides and innate immunity. *J. Endotoxin Res.* **2001**, *7*, 167–202. [[CrossRef](#)] [[PubMed](#)]
25. Schramek, S.; Radziejewska-Lebrecht, J.; Mayer, H. 3-C-branched aldoses in lipopolysaccharide of phase I *Coxiella burnetii* and their role as immunodominant factors. *FEBS J.* **1985**, *148*, 455–461.
26. Skultety, L.; Toman, R.; Patoprsty, V. A comparative study of lipopolysaccharides from two *Coxiella burnetii* strains considered to be associated with acute and chronic Q fever. *Polymers* **1996**, *35*, 189–194.
27. Toman, R.; Hussein, A.; Palkovic, P.; Ftacek, P. Structural properties of lipopolysaccharides from *Coxiella burnetii* strains henzerling and S. *Ann. N. Y. Acad. Sci.* **2003**, *990*, 563–567. [[CrossRef](#)] [[PubMed](#)]

28. Toman, R.; Hussein, A.; Slaba, K.; Skultety, E. Further structural characteristics of the lipopolysaccharide from *Coxiella burnetii* strain nine mile in low virulent phase II. *Acta Virol.* **2003**, *47*, 129–130. [[PubMed](#)]
29. Toman, R.; Skultety, L. Structural study on a lipopolysaccharide from *Coxiella burnetii* strain nine mile in avirulent phase II. *Carbohydr. Res.* **1996**, *283*, 175–185. [[CrossRef](#)]
30. Toman, R.; Skultety, L.; Ftacek, P.; Hricovini, M. NMR study of virenose and dihydrohydroxystreptose isolated from *Coxiella burnetii* phase I lipopolysaccharide. *Carbohydr. Res.* **1998**, *306*, 291–296. [[CrossRef](#)]
31. Vadovic, P.; Ihnatko, R.; Toman, R. Composition and structure of lipid A of the intracellular bacteria *Piscirickettsia salmonis* and *Coxiella burnetii*. In *BSL3 and BSL4 Agents*; Stulik, J., Toman, R., Butaye, P., Ulrich, R.G., Eds.; Wiley-Blackwell: Hoboken, NJ, USA, 2011; pp. 139–144.
32. Vadovic, P.; Slaba, K.; Fodorova, M.; Skultety, L.; Toman, R. Structural and functional characterization of the glycan antigens involved in immunobiology of Q fever. *Ann. N. Y. Acad. Sci.* **2005**, *1063*, 149–153. [[CrossRef](#)] [[PubMed](#)]
33. Toman, R.; Garidel, P.; Andra, J.; Slaba, K.; Hussein, A.; Koch, M.H.; Brandenburg, K. Physicochemical characterization of the endotoxins from *Coxiella burnetii* strain priscilla in relation to their bioactivities. *BMC Biochem.* **2004**, *5*, 1. [[CrossRef](#)] [[PubMed](#)]
34. Hackstadt, T.; Peacock, M.G.; Hitchcock, P.J.; Cole, R.L. Lipopolysaccharide variation in *Coxiella burnetii*: Intrastrain heterogeneity in structure and antigenicity. *Infect. Immun.* **1985**, *48*, 359–365. [[PubMed](#)]
35. Thompson, H.A.; Hoover, T.A.; Vodkin, M.H.; Shaw, E.I. Do chromosomal deletions in the lipopolysaccharide biosynthetic regions explain all cases of phase variation in *Coxiella burnetii* strains? An update. *Ann. N. Y. Acad. Sci.* **2003**, *990*, 664–670. [[CrossRef](#)] [[PubMed](#)]
36. Narasaki, C.T.; Mertens, K.; Samuel, J.E. Characterization of the GDP-D-mannose biosynthesis pathway in *Coxiella burnetii*: The initial steps for GDP- β -D-virenose biosynthesis. *PLoS ONE* **2011**, *6*, e25514. [[CrossRef](#)] [[PubMed](#)]
37. Capo, C.; Moynault, A.; Collette, Y.; Olive, D.; Brown, E.J.; Raoult, D.; Mege, J.L. *Coxiella burnetii* avoids macrophage phagocytosis by interfering with spatial distribution of complement receptor 3. *J. Immunol.* **2003**, *170*, 4217–4225. [[CrossRef](#)] [[PubMed](#)]
38. Honstetter, A.; Ghigo, E.; Moynault, A.; Capo, C.; Toman, R.; Akira, S.; Takeuchi, O.; Lepidi, H.; Raoult, D.; Mege, J.L. Lipopolysaccharide from *Coxiella burnetii* is involved in bacterial phagocytosis, filamentous actin reorganization, and inflammatory responses through toll-like receptor 4. *J. Immunol.* **2004**, *172*, 3695–3703. [[CrossRef](#)] [[PubMed](#)]
39. Vetvicka, V.; Thornton, B.P.; Ross, G.D. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of IC3B-opsinized target cells. *J. Clin. Investig.* **1996**, *98*, 50–61. [[CrossRef](#)] [[PubMed](#)]
40. Meconi, S.; Capo, C.; Remacle-Bonnet, M.; Pommier, G.; Raoult, D.; Mege, J.L. Activation of protein tyrosine kinases by *Coxiella burnetii*: Role in actin cytoskeleton reorganization and bacterial phagocytosis. *Infect. Immun.* **2001**, *69*, 2520–2526. [[CrossRef](#)] [[PubMed](#)]
41. Conti, F.; Boucherit, N.; Baldassarre, V.; Trouplin, V.; Toman, R.; Mottola, G.; Mege, J.L.; Ghigo, E. *Coxiella burnetii* lipopolysaccharide blocks p38 α -MAPK activation through the disruption of TLR-2 and TLR-4 association. *Front. Cell. Infect. Microbiol.* **2015**, *4*, 182. [[CrossRef](#)] [[PubMed](#)]
42. Meconi, S.; Jacomo, V.; Boquet, P.; Raoult, D.; Mege, J.L.; Capo, C. *Coxiella burnetii* induces reorganization of the actin cytoskeleton in human monocytes. *Infect. Immun.* **1998**, *66*, 5527–5533. [[PubMed](#)]
43. Patil, S.; Jedsadayamata, A.; Wencel-Drake, J.D.; Wang, W.; Knezevic, I.; Lam, S.C. Identification of a talin-binding site in the integrin β_3 subunit distinct from the nply regulatory motif of post-ligand binding functions. The talin N-terminal head domain interacts with the membrane-proximal region of the β_3 cytoplasmic tail. *J. Biol. Chem.* **1999**, *274*, 28575–28583. [[CrossRef](#)] [[PubMed](#)]
44. Boucherit, N.; Barry, A.O.; Mottola, G.; Trouplin, V.; Capo, C.; Mege, J.L.; Ghigo, E. Effects of *Coxiella burnetii* on mapkinases phosphorylation. *FEMS Immunol. Med. Microbiol.* **2012**, *64*, 101–103. [[CrossRef](#)] [[PubMed](#)]
45. Benoit, M.; Barbarat, B.; Bernard, A.; Olive, D.; Mege, J.L. *Coxiella burnetii*, the agent of Q fever, stimulates an atypical M2 activation program in human macrophages. *Eur. J. Immunol.* **2008**, *38*, 1065–1070. [[CrossRef](#)] [[PubMed](#)]
46. Benoit, M.; Desnues, B.; Mege, J.L. Macrophage polarization in bacterial infections. *J. Immunol.* **2008**, *181*, 3733–3739. [[CrossRef](#)] [[PubMed](#)]

47. Ghigo, E.; Honstetter, A.; Capo, C.; Gorvel, J.P.; Raoult, D.; Mege, J.L. Link between impaired maturation of phagosomes and defective *Coxiella burnetii* killing in patients with chronic Q fever. *J. Infect. Dis.* **2004**, *190*, 1767–1772. [[CrossRef](#)] [[PubMed](#)]
48. Honstetter, A.; Imbert, G.; Ghigo, E.; Gouriet, F.; Capo, C.; Raoult, D.; Mege, J.L. Dysregulation of cytokines in acute Q fever: Role of interleukin-10 and tumor necrosis factor in chronic evolution of Q fever. *J. Infect. Dis.* **2003**, *187*, 956–962. [[CrossRef](#)] [[PubMed](#)]
49. Ghigo, E.; Capo, C.; Raoult, D.; Mege, J.L. Interleukin-10 stimulates *Coxiella burnetii* replication in human monocytes through tumor necrosis factor down-modulation: Role in microbicidal defect of Q fever. *Infect. Immun.* **2001**, *69*, 2345–2352. [[CrossRef](#)] [[PubMed](#)]
50. Parry, R.V.; Chemnitz, J.M.; Frauwirth, K.A.; Lanfranco, A.R.; Braunstein, I.; Kobayashi, S.V.; Linsley, P.S.; Thompson, C.B.; Riley, J.L. CTLA-4 and PD-1 receptors inhibit t-cell activation by distinct mechanisms. *Mol. Cell. Biol.* **2005**, *25*, 9543–9553. [[CrossRef](#)] [[PubMed](#)]
51. Freeman, G.J.; Wherry, E.J.; Ahmed, R.; Sharpe, A.H. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. *J. Exp. Med.* **2006**, *203*, 2223–2227. [[CrossRef](#)] [[PubMed](#)]
52. Ka, M.B.; Gondois-Rey, F.; Capo, C.; Textoris, J.; Million, M.; Raoult, D.; Olive, D.; Mege, J.L. Imbalance of circulating monocyte subsets and PD-1 dysregulation in Q fever endocarditis: The role of IL-10 in PD-1 modulation. *PLoS ONE* **2014**, *9*, e107533. [[CrossRef](#)] [[PubMed](#)]
53. Zamboni, D.S.; Mortara, R.A.; Freymuller, E.; Rabinovitch, M. Mouse resident peritoneal macrophages partially control in vitro infection with *Coxiella burnetii* phase II. *Microbes Infect.* **2002**, *4*, 591–598. [[CrossRef](#)]
54. Brumell, J.H.; Scidmore, M.A. Manipulation of Rab GTPase function by intracellular bacterial pathogens. *Microbiol. Mol. Biol. Rev.* **2007**, *71*, 636–652. [[CrossRef](#)] [[PubMed](#)]
55. Bucci, C.; Thomsen, P.; Nicoziani, P.; McCarthy, J.; van Deurs, B. Rab7: A key to lysosome biogenesis. *Mol. Biol. Cell* **2000**, *11*, 467–480. [[CrossRef](#)] [[PubMed](#)]
56. Barry, A.O.; Mege, J.L.; Ghigo, E. Hijacked phagosomes and leukocyte activation: An intimate relationship. *J. Leukoc. Biol.* **2011**, *89*, 373–382. [[CrossRef](#)] [[PubMed](#)]
57. Cabrera, M.; Ostrowicz, C.W.; Mari, M.; LaGrassa, T.J.; Reggiori, F.; Ungermann, C. VPS41 phosphorylation and the Rab YPT7 control the targeting of the hops complex to endosome-vacuole fusion sites. *Mol. Biol. Cell* **2009**, *20*, 1937–1948. [[CrossRef](#)] [[PubMed](#)]
58. Nickerson, D.P.; Brett, C.L.; Merz, A.J. VPS-C complexes: Gatekeepers of endolysosomal traffic. *Curr. Opin. Cell Biol.* **2009**, *21*, 543–551. [[CrossRef](#)] [[PubMed](#)]
59. Peralta, E.R.; Martin, B.C.; Edinger, A.L. Differential effects of tbc1d15 and mammalian VPS39 on Rab7 activation state, lysosomal morphology, and growth factor dependence. *J. Biol. Chem.* **2010**, *285*, 16814–16821. [[CrossRef](#)] [[PubMed](#)]
60. Rink, J.; Ghigo, E.; Kalaidzidis, Y.; Zerial, M. Rab conversion as a mechanism of progression from early to late endosomes. *Cell* **2005**, *122*, 735–749. [[CrossRef](#)] [[PubMed](#)]
61. Zick, M.; Wickner, W. Phosphorylation of the effector complex hops by the vacuolar kinase YCK3P confers rab nucleotide specificity for vacuole docking and fusion. *Mol. Biol. Cell* **2012**, *23*, 3429–3437. [[CrossRef](#)] [[PubMed](#)]
62. Sandoz, K.M.; Sturdevant, D.E.; Hansen, B.; Heinzen, R.A. Developmental transitions of *Coxiella burnetii* grown in axenic media. *J. Microbiol. Methods* **2013**, *96*, 104–110. [[CrossRef](#)] [[PubMed](#)]
63. Kuley, R.; Smith, H.E.; Frangoulidis, D.; Smits, M.A.; Jan Roest, H.I.; Bossers, A. Cell-free propagation of *Coxiella burnetii* does not affect its relative virulence. *PLoS ONE* **2015**, *10*, e0121661. [[CrossRef](#)] [[PubMed](#)]

